Molecular structure of Risperidone-d4, CAS Number: 1020719-76-9
Risperidone-d4 (CAS 1020719-76-9)
See product citations (2)
Alternate Names:
3-[2-4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one-d4
Application:
Risperidone-d4 is A deuterated version of Risperidone
CAS Number:
1020719-76-9
Purity:
98% Isotopic Purity 99%
Molecular Weight:
414.51
Molecular Formula:
C23H23D4FN4O2
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Risperidone-d4 is a deuterium-labeled derivative of risperidone, a potent antagonist of serotonin and dopamine receptors.Risperidone-d4 acts by binding to and blocking the activity of serotonin 5-HT2 and dopamine D2 receptors in the brain, thereby modulating neurotransmitter signaling pathways. Risperidone-d4′s mechanism of action involves inhibiting the binding of serotonin and dopamine to their respective receptors, leading to altered neurotransmission and downstream effects on neuronal function. Its deuterium-labeled structure allows for precise tracking and quantification in pharmacokinetic and metabolic studies, contributing to a deeper understanding of risperidone′s pharmacokinetic profile and metabolic fate.
Risperidone-d4 (CAS 1020719-76-9) References
- Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring. | Ansermot, N., et al. 2013. J Chromatogr A. 1292: 160-72. PMID: 23380367
- Postmortem femoral blood concentrations of risperidone. | Linnet, K. and Johansen, SS. 2014. J Anal Toxicol. 38: 57-60. PMID: 24324228
- Comparison of conventional liquid chromatography-tandem mass spectrometry versus microflow liquid chromatography-tandem mass spectrometry within the framework of full method validation for simultaneous quantification of 40 antidepressants and neuroleptics in whole blood. | Steuer, AE., et al. 2015. J Chromatogr A. 1381: 87-100. PMID: 25596763
- In vitro-in vivo correlation of parenteral risperidone polymeric microspheres. | Shen, J., et al. 2015. J Control Release. 218: 2-12. PMID: 26423236
- Quantification of 16 QT-prolonging Drugs and Metabolites in Human Postmortem Blood and Cardiac Tissue Using UPLC-MS-MS. | Mikkelsen, CR., et al. 2016. J Anal Toxicol. 40: 286-93. PMID: 26977106
- A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations. | Yamamoto, Y., et al. 2017. Pharm Res. 34: 333-351. PMID: 27864744
- Confirmation of metabolites of the neuroleptic drug prothipendyl using human liver microsomes, specific CYP enzymes and authentic forensic samples-Benefit for routine drug testing. | Krämer, M., et al. 2017. J Pharm Biomed Anal. 145: 517-524. PMID: 28756170
- Detecting Anti-IIa and Anti-Xa Direct Oral Anticoagulant (DOAC) Agents in Urine using a DOAC Dipstick. | Harenberg, J., et al. 2019. Semin Thromb Hemost. 45: 275-284. PMID: 30134449
- In vitro-in vivo correlation of parenteral PLGA microspheres: Effect of variable burst release. | Andhariya, JV., et al. 2019. J Control Release. 314: 25-37. PMID: 31654687
- A simple and rapid LC-MS/MS method for the simultaneous determination of eight antipsychotics in human serum, and its application to therapeutic drug monitoring. | Cao, Y., et al. 2020. J Chromatogr B Analyt Technol Biomed Life Sci. 1147: 122129. PMID: 32416590
- Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of Risperidone. | Perlstein, I., et al. 2022. Clin Pharmacol Drug Dev. 11: 865-877. PMID: 35245409
- In vitro-in vivo correlation of PLGA microspheres: Effect of polymer source variation and temperature. | Wan, B., et al. 2022. J Control Release. 347: 347-355. PMID: 35569590
- A Transversal Approach Combining In Silico, In Vitro and In Vivo Models to Describe the Metabolism of the Receptor Interacting Protein 1 Kinase Inhibitor Sibiriline. | Pelletier, R., et al. 2022. Pharmaceutics. 14: PMID: 36559159
Inhibitor of:
DOR.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Risperidone-d4, 2.5 mg | sc-219978 | 2.5 mg | $347.00 |